Interviews

Vincent Picozzi, MD, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.

David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.<br /> &nbsp;

Scott Kopetz, MD, PhD, discusses&nbsp;the combination of regorafenib and nivolumab for patients with colorectal cancerthe combination of regorafenib and nivolumab for patients with colorectal cancer.

Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.

Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.

Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.

Tania Jain, MBBS, discusses the current treatment options for graft-versus-host-disease, a known complication of allogeneic stem cell transplant, which is the only curative treatment option for patients with myelofibrosis.

Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Heather Wakelee, MD, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors in patients harboring an&nbsp;EGFR&nbsp;mutation.

Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.

Sonali M. Smith, MD, discusses&nbsp;how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.<br /> &nbsp;

Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with&nbsp;<a>lung cancer.</a>&nbsp;He shares his advice on what to do for patients who need therapy immediately, as well.

Jeff P. Sharman, MD, discusses the secondary end points from the&nbsp;<u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN&nbsp;trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

Kevin Hughes, MD, discusses how genetic testing has changed and how much testing should be done for patients with breast cancer.

Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br /> &nbsp;

Massimo Lazzari, MD, discusses findings from an analysis of the urinary microbiota in patients with bladder cancer.

Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.

Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.

Eugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.

Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.

Bradley McGregor, MD, discusses a trial investigating atezolizumab and bevacizumab in patients with metastatic renal cell carcinoma and variant histologies and/or sarcomatoid features.

Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with&nbsp;<em>EGFR</em>-mutant lung cancer.

Scott Kopetz, MD, PhD, discusses the treatment of patients with colorectal cancer and how it differs from other cancer regimens.

Benjamin P. Levy, MD, discusses biomarkers that have led to the development therapies with high response rates in lung cancer.

Andre Goy, MD, discusses the current treatments, specifically Bruton&rsquo;s tyrosine kinase, for patients with mantle cell lymphoma and what the efficacy has been with this type of treatment.

Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.<br /> &nbsp;